T he association among oxidative modifications of LDL, 1,2 reduced antioxidant defenses, 3 and unstable angina has been well documented. Moreover, numerous studies have shown that the dietary intake of vitamin E is inversely correlated with the risk of cardiovascular disease 4 and that vitamin E supplementation reduced nonfatal coronary events in a randomized clinical trial in patients with coronary artery disease. 5 Recently, a series of bioactive prostaglandin (PG)F 2 -like compounds (isoprostanes) have been discovered 6 that are produced from arachidonic acid through a nonenzymatic process of lipid peroxidation, catalyzed by oxygen free radicals on cell membranes and LDL particles. Among these products, of particular interest is 8-iso-PGF 2␣ (also known as iPF 2␣ -III), which induces vasoconstriction and amplifies the response of human platelets to other agonists (for a review, see Patrono and FitzGerald 7 ). F 2 -isoprostanes can be reliably measured in both plasma and urine 8, 9 and have been shown to be increased in association with cigarette smoking, 10, 11 diabetes mellitus, 12 and hypercholesterolemia. 13, 14 Consistent with the hypothesis of a contribution of 8-iso-PGF 2␣ to persistent platelet activation in these settings, dose-dependent suppression of F 2 -isoprostane formation by vitamin E supplementation was associated with significant reductions in 11-dehydro-thromboxane (TX)B 2 (TXM) excretion in diabetic 12 and hypercholesterolemic 13 patients.
Episodic increases in TXA 2 biosynthesis have been reported in patients with unstable angina. 15, 16 Enhanced TX biosynthesis in this setting is likely to reflect episodes of platelet activation, because it was largely suppressed with low-dose aspirin. 16 However, despite Ͼ95% suppression of the cyclooxygenase (COX) activity of platelet prostaglandin H synthase (PGHS-1) by aspirin, incomplete suppression of TXM excretion has been detected in some patients with unstable angina. 16 We speculated that increased oxidant stress in unstable angina could induce the generation of 8-iso-PGF 2␣ and other biologically active isoeicosanoids and that these compounds could in turn contribute to aspirin-insensitive TX biosynthesis in this setting. Therefore, in the present study, we investigated whether 8-iso-PGF 2␣ formation is altered in patients with severe unstable angina compared with matched patients with stable angina and healthy subjects and whether it correlates with the rate of TXA 2 biosynthesis. Additional studies were performed to assess the influence of myocardial ischemia per se and COX-1 or -2 inhibition on 8-iso-PGF 2␣ and TXA 2 biosynthesis.
Methods

Subjects
Between February 1993 and June 1998, we studied 32 patients with severe unstable angina (Braunwald class IIIB 17 ), 32 patients with chronic stable angina, 4 patients with active variant angina, and 40 healthy volunteers. None of the participating subjects were taking vitamins, dietary supplements, or drugs with known antioxidant activity during the study. Conventional therapy was allowed as determined with clinical judgment. Informed consent was obtained from each subject. The study protocol was approved by the institutional ethics committee. The baseline clinical characteristics of patients are given in the Table.
Study Design
We conducted a cross-sectional comparison of urinary 8-iso-PGF 2␣ and TXM in patients with unstable angina (nϭ20) or stable angina (nϭ20) and 40 age-and gender-matched control subjects (22 men and 18 women, mean age 54Ϯ8 years). Moreover, patients with stable and unstable angina were also matched for hypercholesterolemia, diabetes, cigarette smoking, hypertension, and drug therapy to minimize potential confounders (Table) . Each patient underwent an overnight urine collection. Urine samples were added with the antioxidant 4-hydroxy-tempo (1 mmol/L; Sigma Chemical Co) and stored at Ϫ20°C until extraction.
To assess the potential influence of myocardial ischemia on F 2 -isoprostane and TX biosynthesis, 2 additional studies were performed. In the first, 12 men with stable angina (mean age 62Ϯ7 years) were studied. On admission, these patients were monitored with Holter monitoring during the first day of hospitalization to exclude the presence of spontaneous myocardial ischemia. Patients were subjected to an exercise stress test with bicycle ergometry during continuous 12-lead ECG monitoring to assess the relation of 8-iso-PGF 2␣ excretion to the occurrence of myocardial ischemia. Four consecutive 6-hour urine samples were collected during the first 24 hours of study, and 2 consecutive urine samples (at 30 minutes and 6 hours, respectively) were collected after exercise-induced myocardial ischemia. In the second study, we measured 8-iso-PGF 2␣ in 46 urine samples collected from 4 patients with active variant angina during 96 hours of observation.
Because small amounts of 8-iso-PGF 2␣ can be formed by human platelets and monocytes through a COX-1-and -2-dependent mechanism, 7 respectively, we also evaluated whether the inhibition of COX had any influence on 8-iso-PGF 2␣ excretion. Thus, to explore the potential contribution of platelet COX-1, we measured 8-iso-PGF 2␣ and TXM in 47 urine samples collected from 8 patients with stable angina (mean age 62Ϯ7 years) taking low-dose aspirin (100 mg/d) and compared it with 17 samples obtained from 4 patients with stable angina (mean age 63Ϯ7 years) who were not taking any antiplatelet drug at the time of study due to contraindications. To evaluate the potential contribution of monocyte COX-2, 12 patients with unstable angina (6 men and 6 women, mean age 64Ϯ11 years) were randomly assigned to receive (1) conventional therapy plus 1 mg/kg 6-methyl-prednisolone (6-MP) BID for 2 days, administered in a 25-minute intravenous infusion (nϭ6) or (2) conventional therapy plus placebo (as 0.9% NaCl solution) BID for 2 days (nϭ6). All patients received 100 mg/d aspirin during the study. Twelve 6-hour urine samples were collected from each patient, and a total of 144 urine samples were analyzed for 8-iso-PGF 2␣ and TXM.
To investigate the relationship between endogenous plasma antioxidants and F 2 -isoprostane biosynthesis, blood and urine samples were obtained from 14 patients with severe unstable angina (7 men and 7 women, mean age 54Ϯ9 years) after a 12-hour fast for the determination of plasma vitamin E and urinary 8-iso-PGF 2␣ . Blood was drawn into test tubes that contained EDTA (2.7 mmol/L) and were separated within 1 hour after sampling. Vitamin E plasma content was determined with HPLC. 18 
Urinary Eicosanoid Assays
Urinary 8-iso-PGF 2␣ and TXM levels were measured according to previously described and validated radioimmunoassay methods. 9, 19 
Statistical Analysis
For the clinical data, variables were compared with the use of the 2 test. The biochemical data were analyzed according to nonparametric methods. An ANOVA was performed with the Kruskal-Wallis method. Subsequent pairwise comparisons were made with the Mann-Whitney U test with corrections for multiple comparisons. The differences between baseline and postprocedural values were analyzed with the Wilcoxon signed-rank test. Moreover, the association of eicosanoid measurements with other biochemical parameters was assessed with the Spearman rank correlation test. The number of ischemic episodes and the ischemic burden are expressed as median and range; the remaining variables are reported as meanϮSD. Statistical significance was considered to be indicated by a P value of Ͻ0.05, except for multiple comparisons, where the threshold for statistical significance was defined on the basis of the number of comparisons.
Results
Urinary 8-iso-PGF 2␣ excretion was significantly higher in patients with unstable angina (339Ϯ122 pg/mg creatinine, meanϮSD, nϭ20) than in matched patients with stable angina (236Ϯ83 pg/mg creatinine, nϭ20, Pϭ0.001) and in healthy subjects (192Ϯ71 pg/mg creatinine, nϭ40, PϽ0.0001) (Figure 1 ). Patients with unstable angina taking low-dose aspirin had significantly higher TXM excretions than did patients with stable angina (532Ϯ227 versus 194Ϯ89 pg/mg creatinine, nϭ20, PϽ0.0001) (Figure 2) . A statistically significant correlation was found between 8-iso-PGF 2␣ and TXM excretion in patients with unstable angina (ϭ0.721, PϽ0.0001) (Figure 3) but not in patients with stable angina or healthy subjects (not shown). Moreover, as shown in Figure 4 , a statistically significant inverse correlation was found between plasma levels of vitamin E and urinary 8-iso-PGF 2␣ (ϭϪ0.710, Pϭ0.004) and TXM (ϭϪ0.696, Pϭ0.006) in patients with unstable angina.
Effects of Myocardial Ischemia
By investigating 8-iso-PGF 2␣ excretion before and after a positive exercise stress test in 12 patients with chronic stable angina, we sought to determine whether myocardial ischemia per se was responsible for triggering the enhanced biosynthesis of F 2 isoprostanes. Urinary 8-iso-PGF 2␣ did not increase as a result of myocardial ischemia, as reflected with values of 234Ϯ128 (nϭ48) before and 219Ϯ111 (nϭ24) pg/mg creatinine after effort-induced myocardial ischemia (PϭNS) (Figure 5) . Moreover, to exclude that the severity of ischemia caused by effort in stable patients could be insufficient to cause detectable lipid peroxidation, we also measured 8-iso-PGF 2␣ angina than in patients with unstable angina. Despite this, the level of lipid peroxidation in patients with variant angina was comparable to that of patients with stable angina and lower than of patients with unstable angina. Moreover, in patients with variant angina, 8-iso-PGF 2␣ excretion did not differ between the samples collected during myocardial ischemia (249Ϯ119 pg/mg creatinine, nϭ19) and those collected during the ischemia-free periods (262Ϯ129 pg/mg creatinine, nϭ27).
Effects of COX Inhibition
Because relatively small amounts of 8-iso-PGF 2␣ can be formed enzymatically through the COX activity of platelet PGHS-1 and monocyte PGHS-2, we explored the effects of COX inhibition on the urinary excretion of 8-iso-PGF 2␣ . Thus, we used aspirin and 6-MP to investigate the mechanism or mechanisms of F 2 -isoprostane formation in ischemic heart disease. Aspirin irreversibly acetylates the serine residue at position 529 (Ser529) in the polypeptide chain of PGHS-1. 20 By virtue of this unique mechanism of action, the daily intake of low doses of aspirin selectively suppresses platelet TXA 2 synthesis in a cumulative fashion. 21 As shown in Figure 6 , urinary 8-iso-PGF 2␣ excretion was not significantly different in patients with stable angina treated with low-dose aspirin versus those untreated with low-dose aspirin, despite a statistically significant difference in TXM excretion.
Previous in vitro evidence demonstrates that glucocorticoids can prevent inducible monocyte 8-iso-PGF 2␣ production in association with the suppression of PGHS-2 induction. 22 The excretion rates of urinary 8-iso-PGF 2␣ measured before, during, and after 6-MP or placebo infusions are depicted in Figure 7 . In patients randomized to receive 6-MP, 8-iso-PGF 2␣ formation did not show any statistically significant change between the first and the last day of study (252Ϯ169 versus 215Ϯ147 pg/mg creatinine). Moreover, no statistically significant differences were found between placebo and 6-MP treatment. These findings are consistent with a COXindependent mechanism of F 2 -isoprostane formation in unstable angina.
Discussion
Previous studies have examined the role of lipid peroxidation in acute coronary syndromes through the measurements of malondialdehyde 1 or the susceptibility of the LDL of the patient to oxidation in vitro. 2 However, malondialdehyde is a byproduct of COX activity in platelets, 23 thus resulting in lack of specificity in clinical syndromes characterized by platelet activation. Moreover, it is unclear whether the wide variations reported in the susceptibility of LDL from different individuals to oxidation ex vivo have any relevance to the actual extent of LDL oxidation in vivo.
In the present study, we used the urinary excretion of the F 2 -isoprostane 8-iso-PGF 2␣ as a marker of in vivo lipid peroxidation. 6, 7 The measurement of this chemically stable compound has several distinct advantages over other markers of oxidant stress. (1) It reflects a nonenzymatic process of lipid peroxidation of an ubiquitous, endogenous substrate (ie, arachidonic acid) that is catalyzed by oxygen radicals. 6 (2) Once released from cell membranes or LDL, 8-iso-PGF 2␣ circulates in peripheral venous blood. 8 (3) Urinary excretion of this metabolite has been well characterized in humans. 8, 9 This analytical approach has been used previously to demonstrate enhanced lipid peroxidation in association with advanced age, 9 cigarette smoking, 10,11 diabetes mellitus, 12 and hypercholesterolemia, 13, 14 as well as after coronary artery reperfusion. 24, 25 In the present study, we found that the formation and urinary excretion of 8-iso-PGF 2␣ are abnormally elevated Figure 5 . Effect of effort-induced myocardial ischemia on urinary excretion of 8-iso-PGF 2␣ . Excretion rates were measured in 12 patients with chronic stable angina on 2 consecutive days before and after a positive exercise stress test. Figure 6 . Urinary excretion rates of 8-iso-PGF 2␣ (left) and 11-dehydro-TXB 2 (right) in patients with stable angina with chronic aspirin (ASA) therapy compared with those not taking any antiplatelet treatment. Platelet COX inhibition, as reflected by suppression of TX biosynthesis, was not associated with any detectable difference in urinary 8-iso-PGF 2␣ . Numbers in parentheses represent number of urine samples from which mean value for each group was derived. in the vast majority of patients with severe unstable angina who were carefully characterized for other variables that could influence in vivo lipid peroxidation (Table) . This is the first report of enhanced in vivo lipid peroxidation in patients with unstable angina. Previously, Delanty et al 24 reported elevated levels of F 2 -isoprostanes in patients with acute myocardial infarction who were undergoing thrombolysis.
We further examined whether enhanced F 2 -isoprostane formation is a consequence of myocardial ischemia. The studies in patients with stable angina and active variant angina argue against this possibility by showing substantially unchanged rates of 8-iso-PGF 2␣ excretion up to 6 hours after exercise-induced myocardial ischemia ( Figure  5 ) and during persistent transmural ischemia induced by coronary artery spasm. Similarly, Reilly et al 25 reported that patients undergoing coronary angioplasty for ischemic symptoms did not have elevated preprocedural levels of 8-iso-PGF 2␣ .
Because platelet COX activity can be a source of relatively small amounts of 8-iso-PGF 2␣ compared with TXB 2 , 26 we asked whether enhanced urinary excretion of the former and its correlation with TXM excretion in unstable angina might simply reflect an ongoing process of platelet activation in this setting. This seems unlikely because (1) platelet COX-1 activity was blocked by aspirin treatment in all patients and (2) aspirin-insensitive TXM excretion in unstable angina is likely to reflect extraplatelet sources of TXA 2 biosynthesis possibly driven by COX-2 induction. 27 Moreover, the study in patients with chronic stable angina that compared metabolite excretion in the presence and absence of platelet COX blockade by low-dose aspirin clearly shows that the suppression of TXA 2 biosynthesis is not associated with any detectable change in F 2 -isoprostane formation ( Figure 6 ). These results are consistent with a platelet COX-independent mechanism of formation of 8-iso-PGF 2␣ in ischemic heart disease, as demonstrated in other clinical settings. 9, 12, 13 The induction of PGHS-2 in monocytes/macrophages in response to a local inflammatory/mitogenic milieu can provide a source of aspirin-insensitive TXA 2 biosynthesis in unstable angina, as suggested previously 27 and confirmed in the present study. Moreover, the COX activity of monocyte PGHS-2 can also generate small amounts of 8-iso-PGF 2␣ in vitro. 22 Thus, to exclude the contribution of an acute inflammatory reaction 28 to enhanced 8-iso-PGF 2␣ formation in unstable angina, we exploited the capacity of glucocorticoids to suppress monocyte PGHS-2 induction in response to lipopolysaccharide, 29 thereby preventing COX-2-dependent 8-iso-PGF 2␣ formation. 22 The failure of intravenous 6-MP to suppress 8-iso-PGF 2␣ excretion in patients with unstable angina (Figure 7 ) argues against a COX-2-dependent mechanism of F 2 -isoprostane formation in this setting.
Having established that enhanced excretion of 8-iso-PGF 2␣ is likely to reflect a nonenzymatic process of lipid peroxidation in patients with unstable angina, we examined the correlation between its rate of formation and plasma vitamin E levels. Vitamin E is a potent, lipid soluble antioxidant that is present in plasma and LDL. Our previous studies performed in hypercholesterolemic 13 and diabetic 12 patients demonstrated dose-dependent reductions in F 2 -isoprostane formation in response to short-term vitamin E supplementation. Consistent with these results, we found a statistically significant inverse correlation between plasma vitamin E levels and 8-iso-PGF 2␣ excretion rates in patients with unstable angina (Figure 4) . Thus, most likely, enhanced lipid peroxidation in patients with severe unstable angina reflects an altered oxidant/antioxidant balance. The mechanism or mechanisms and location of the oxidant species responsible for increased formation of F 2 -isoprostanes remain unanswered in the present study because of the obvious limitations inherent to urinary measurements. The localization of distinct isoprostanes 30 and other products of lipid peroxidation 31 in carotid atherosclerotic lesions and their relationship to plaque instability 31 suggest that a similar scenario may occur in coronary plaques.
In patients with unstable angina, Ϸ50% of the individual variation in aspirin-insensitive TXA 2 biosynthesis could be accounted for by the individual variation in 8-iso-PGF 2␣ formation (Figure 3) . Although a common factor (eg, acute inflammation) might trigger both aspirin-insensitive TXA 2 biosynthesis and nonenzymatic formation of F 2 - isoprostanes and thus contribute to the correlation between the 2, this seems unlikely in view of the intervention studies discussed earlier and of the correlation with endogenous vitamin E levels. A more likely explanation for this correlation between 8-iso-PGF 2␣ and TXM excretion, detectable in unstable angina but not in chronic stable angina, is that enhanced lipid peroxidation and formation of bioactive isoeicosanoids represent an important determinant of aspirin-insensitive TX biosynthesis. COX-2 induction in response to a variety of lipid mediators, including substrates, products, and inhibitors of PGH-synthase, has recently been described in mammary epithelial cells in vitro. 32 Concentrations of 8-iso-PGF 2␣ in the range of 1 nmol/L to 1 mol/L induce a dose-dependent increase in platelet shape change, calcium release from intracellular stores, and inositol phosphates. 7 Moreover, 8-iso-PGF 2␣ increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of nitric oxide. 33 Furthermore, 8-iso-PGF 2␣ causes dose-dependent, irreversible platelet aggregation in the presence of concentrations of collagen, ADP, arachidonic acid, and PGH 2 /TXA 2 analogs that, when acting alone, fail to aggregate platelets. 34 Although platelet-active concentrations of 8-iso-PGF 2␣ may not be achieved in circulating blood, it should be pointed out that this compound is only 1 of a series of biologically active isoeicosanoids formed through a similar non-COX mechanism of lipid peroxidation. 35 In fact, up to 64 F 2 -isoprostanes may be formed, and similar families of isomers of other prostaglandins and lipoxygenase and epoxygenase products are likely to be generated. 35 This level of complexity constrains the interpretation of studies that focus on a single isomer, particularly when attempting to define their likely role as bioactive autacoids in vivo. Thus, both PGHS-2-derived TXA 2 and nonenzymatic F 2 -isoprostane formation might represent 2 important eicosanoid mechanisms that contribute to aspirin-insensitive platelet activation in unstable angina. The 2 mechanisms might play a variable role in different patients with unstable angina, depending on the prevalence of an acute inflammatory reaction and its endogenous modulation versus enhanced oxidant stress and its endogenous regulation.
We conclude that increased nonenzymatic formation of F 2 -isoprostanes may provide an important biochemical link between an altered oxidant/antioxidant balance and aspirin-insensitive TX biosynthesis in patients with unstable angina. These results provide a rationale for dosefinding studies of antioxidants in acute coronary syndromes, with F 2 -isoprostane formation used as the primary biochemical end point.
